PT  - JOURNAL ARTICLE
AU  - Mancuso, Patrizia
AU  - Gidaro, Antonio
AU  - Gregato, Giuliana
AU  - Raveane, Alessandro
AU  - Cremonesi, Paola
AU  - Quarna, Jessica
AU  - Caccia, Sonia
AU  - Gusso, Luca
AU  - Cogliati, Chiara
AU  - Bertolini, Francesco
TI  - Viable circulating endothelial cells and their progenitors are increased in Covid-19 patients
AID  - 10.1101/2020.04.29.20085878
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20085878
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085878.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085878.full
AB  - During the course of Covid-19, the disease caused by the new Coronavirus SARS-CoV-2, thrombotic phenomena and/or diffuse vascular damage are frequent, and viral elements have been observed within endothelial cells. Circulating endothelial cells (CECs) and their progenitors (CEPs) are increased in cardiovascular, thrombotic, infectious and cancer diseases. Using a validated flow cytometry procedure, we found that viable CEPs/mL were significantly increased in Covid-19 patients compared to healthy controls. This increase was observed in patients with mild symptoms and not further augmented in patients with severe symptoms. In patients who recovered, CEPs decreased, but were in a range still significantly higher than normal controls. Regarding mature CECs, in Covid-19 patients their absolute number was similar to those observed in healthy controls, but the viable/apoptotic CEC ratio was significantly different. Both mild and severe Covid-19 patients had significantly more viable CECs compared to healthy controls. Patients who recovered had significantly less CECs/mL when compared to controls as well as to mild and severe Covid-19 patients. A positive correlation was found between the copies of SARS-CoV-2 RNA in the cellular fraction and apoptotic CEPs/mL in severe Covid-19 patients. These findings suggest that CECs and CEPs might be investigated as candidate biomarkers of endothelial damage in Covid-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial2020/ST/049Funding StatementSupported in part by AIRC and Italian Ministry of HealthAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data are available upon request